Vital Therapies, Inc.
IMUX US4525EP1011
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -41% | -87% | 7% | -31% | 8% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Nash Duane CB |
0.83 USD |
20,000 Bought |
16,694 USD |
13/06/2025 | 13/06/2025 |
| Nash Duane CB |
0.83 USD |
20,000 Bought |
16,694 USD |
13/06/2025 | 13/06/2025 |
| Tardio Jason PR |
0.79 USD |
12,512 Bought |
9,884 USD |
05/06/2025 | 05/06/2025 |
| Neermann Joerg O |
0.76 USD |
30,000 Bought |
22,800 USD |
04/06/2025 | 05/06/2025 |
| Neermann Joerg O |
0.76 USD |
30,000 Bought |
22,800 USD |
04/06/2025 | 05/06/2025 |
| Tardio Jason PR |
0.79 USD |
12,512 Bought |
9,884 USD |
05/06/2025 | 05/06/2025 |
| Tardio Jason PR |
0.79 USD |
12,512 Bought |
9,884 USD |
05/06/2025 | 05/06/2025 |
| Vitt Daniel CEO |
0.77 USD |
15,000 Bought |
11,550 USD |
04/06/2025 | 04/06/2025 |
| Vitt Daniel CEO |
0.77 USD |
15,000 Bought |
11,550 USD |
04/06/2025 | 04/06/2025 |
| Neermann Joerg O |
0.77 USD |
70,000 Bought |
53,900 USD |
04/06/2025 | 04/06/2025 |